Published • loading... • Updated
PTC Therapeutics (NASDAQ:PTCT) Upgraded at UBS Group
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PTC Therapeutics (NASDAQ:PTCT) Upgraded at UBS Group
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) was upgraded by UBS Group to a “strong-buy” rating in a report released on Wednesday, Zacks reports. A number of other research analysts have also recently commented on PTCT. Morgan Stanley raised their target price on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
